Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article by mHealthIntelligence referenced a study published in the June 2023 issue of The American Journal of Managed Care®(AJMC®). The study, “Economics of a Health System’s Direct-to-Consumer Telemedicine for Its Employees,” found that direct-to-consumer telemedicine service ultimately resulted in a lower per-episode unit cost of care within 7 days, with only a minimal increase in the use of services. This study was also referenced in HealthExec, MedicalXPress, and MedCityNews.
An article from Medical Economics® referenced a study published in the March 2022 issue of AJMC. The study, “Small Practice Participation and Performance in Medicare Accountable Care Organizations,” concluded that Medicare beneficiaries who were attributed to small practices in accountable care organizations had greater savings compared with those who were attributed to large practices.
An article by Forbes referenced an article published on AJMC.com, the website of AJMC. The article, “Violence Against Healthcare Workers: A Rising Epidemic,” featured an opinion piece on how more attention needs to be given to the increasing rate of violence against workers in the health care industry.
An article from CafeMom referenced an article published on AJMC.com. The article, “Racial Disparities Persist in Maternal Morbidity, Mortality and Infant Health,” focused on the increased rate of maternal mortality in the United States, mentioning that Black women were 3 times more likely to die in childbirth compared with White women.
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Oral GC Dose Tapering for MG Linked to Efgartigimod Initiation
August 25th 2025Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen